Review



pam 3 csk 4  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    InvivoGen pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 3709 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/bio_rxiv__64898__2026__05__27__728102-37-1-5
    Average 99 stars, based on 3709 article reviews
    pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars

    Images

    1) Product Images from "Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection"

    Article Title: Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection

    Journal: bioRxiv

    doi: 10.64898/2026.05.27.728102

    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Figure Legend Snippet: Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Techniques Used: Transduction, Infection, Injection

    Related Articles

    High Molecular Weight:

    Article Title: Patterns and trajectories of peripheral inflammatory cytokines, immune tolerance, and lymphocyte differentiation predict transition from acute to chronic low back pain in a sex and age specific manner
    Article Snippet: .. Prior to thawing PBMCs, wells of a 96-well plate were pre-loaded with 50μl RPMI-10 containing nothing (Mock); 100ng PAM 3 CSK 4 (TLR1/2 ligand, Invivogen); 10ng lipopolysaccharide (LPS, TLR4 ligand, Invivogen); 100ng R848 (TLR7/8 ligand, Invivogen); high molecular weight poly I:C-lyovec (MDA5 ligand, Invivogen); ISD-lyovec (cGAS-STING activator, Invivogen); 500ng mouse anti-human CD40 antibody (αCD40, R&D systems MAB6321) with 2μg goat anti-mouse IgG antibody (Jackson ImmunoResearch, for crosslinking); or 200ng anti-CD3 antibody (BioLegend), 200ng Ultra-Leaf anti-CD28 antibody (BioLegend), with 1.6μg goat anti-mouse IgG (for crosslinking). .. After thawing and treating PBMCs with DNAse as described for ‘flow cytometry analyses’ above, cells were counted using a Countess II with trypan blue exclusion (Thermo-Fisher) and 5×10 4 viable PBMCs in 50μl RPMI-10 were added to wells containing each of the 8 conditions.

    other:

    Article Title: Toll-like receptor 1 polymorphism is associated with impaired immune tolerance, dysregulated inflammatory responses to Borrelia burgdorferi , and heightened risk of post-infectious Lyme arthritis
    Article Snippet: PBMCs or THP-1 macrophages were co-cultured with B. burgdorferi or Pam 3 CSK 4 (300 ng/ml; InvivoGen) for 24hr (Stimulated).

    Enzyme-linked Immunosorbent Assay:

    Article Title: Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins
    Article Snippet: PBMCs were pre-stimulated with either actifensin (10 μM) or LL-37 (10 μM; tlrl-l37-5, InvivoGen, Toulouse, France) for 30 min. .. Afterwards, cells were stimulated with Pam 3 CSK 4 (tlrl-pms-1, InvivoGen, Toulouse, France), LPS (tlrl-3pelps, InvivoGen, Toulouse, France), or S. aureus RN4220 for 3 h. Cell-free culture supernatants were collected and analysed for cytokine release using a TNF ELISA kit (88-7346-88, Thermo Fisher Scientific, Darmstadt, Germany). .. For LDH release analysis, PBMCs were incubated with varying concentrations of actifensin for 3.5 h. The culture supernatants were collected and analysed using an LDH Cytotoxicity Detection Kit ( C20300 , Invitrogen, Toulouse, France).



    Similar Products

    pam 3 csk 4  (InvivoGen)
    99
    InvivoGen pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/bio_rxiv__64898__2026__05__27__728102-37-1-5
    Average 99 stars, based on 1 article reviews
    pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    tlr1 2 ligand pam 3 csk 4  (InvivoGen)
    99
    InvivoGen tlr1 2 ligand pam 3 csk 4
    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized <t>Pam</t> <t>3</t> <t>CSK</t> <t>4</t> at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.
    Tlr1 2 Ligand Pam 3 Csk 4, supplied by InvivoGen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pam+3+csk+4/Pam3CSK4/pmc12506935-305-81-89
    Average 99 stars, based on 1 article reviews
    tlr1 2 ligand pam 3 csk 4 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier

    Image Search Results


    Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Journal: bioRxiv

    Article Title: Preclinical antiviral study of a liver-targeted TLR1/2 agonist in an immune-competent mouse model of HBV infection

    doi: 10.64898/2026.05.27.728102

    Figure Lengend Snippet: Six-weeks-old C57BL/6 male mice were mock-transduced or transduced with 10 11 ⍰vge of AAV-HBV 1.3 mer genotype D/serotype ayw for 31 days to allow establishment of chronic infection. At day-35, treatment cycles were started, after mice were evenly grouped according to viremia and HBsAg antigenemia. Mice (n⍰= ⍰7/group) were injected, at indicated days with vehicle (PBS), free/non vectorized Pam 3 CSK 4 at 100 μg/injection, NP-Pam 3 CSK 4 at 5 μg/shot, or NP-Pam 3 CSK 4 at 20 μg/shot. 3TC was administrated continously at approximately 100 mg/kg/day (in drinking water) between days-35 and 64 and days-79 and 90. Blood/serum was collected at indicated times (blood drop symbol). Mice were euthanized at 90 days post-transduction. The different readouts and used techniques for exploitation of blood and liver samples are indicated.

    Article Snippet: Either Pam 3 CSK 4 (InvivoGen, USA) or the near-infrared fluorescent probe DiR XenoLight Dye (λ excitation = 750 nm, λ emission = 770 nm) (Perkin Elmer, USA) was incorporated during the nanoprecipitation.

    Techniques: Transduction, Infection, Injection